These results demonstrate that cetuximab shows therapeutic efficacy via cell cycle arrest at the G1/S phase, DNA damage, and cell death; therefore, cetuximab has potential therapeutic efficacy against EGFR-overexpressing NSCLC and can be used as a targeting vehicle and in combination schemes to improve EGFR-targeted NSCLC therapy. Here, EGFR is linked to non-small cell lung carcinoma.